
Please try another search
Valiant Laboratories, a Paracetamol manufacturer, launched its initial public offering (IPO) today, Wednesday, attracting bids for 17.6 lakh equity shares. This represents a 23% subscription of the total shares offered on the first day of bidding.
Retail investors secured a significant portion of the reserved shares, accounting for 44% of the initial allocation. High-net-worth individuals also participated, purchasing 5% of the reserved shares. However, qualified institutional buyers have yet to participate in the bidding process.
In addition to individual investors, anchor investors purchased INR 45.74 crore worth of shares from Valiant Laboratories on the day of the IPO launch.
The company has set a price range of INR 133-140 per share for its IPO, with an aim to raise INR 152.46 crore. Part of these proceeds will be allocated to its subsidiary VASPL and promoter Dhanvallabh Ventures LLP.
The IPO marks an important milestone for Valiant Laboratories as it seeks to expand its operations and increase its market presence. The participation of retail and high-net-worth investors on the first day of bidding indicates a promising start for the company's public trading journey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.